Cannabis Report
Lithium
Home > Boards > Free Zone > Health and Sciences >

Biotech Values

RSS Feed
      Hide Sticky   Hide Intro
Moderator: DewDiligence Assistants: Biowatch
Search This Board: 
Last Post: 8/17/2018 4:02:32 PM - Followers: 1392 - Board type: Free - Posts Today: 10

Biotech Values is a forum for discussing 
all facets of biotech investing with an emphasis
on fundamental analysis and avoiding scams.
We generally do not discuss microcap stocks.

Compilations
FDA Calendar
Biotech Buyouts/Premiums

Biotech Acronyms
'Way Back' Archive

Cannabis Report
Lithium
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#220531   This one has a ton of Catalyst coming matt24d 08/17/18 04:02:31 PM
#220530   Does anyone have an opinion on ADMA? I ronpopeil 08/17/18 02:11:42 PM
#220529   Both companies—(GILD and ABBV)—have said that US HCV DewDiligence 08/17/18 12:45:23 PM
#220528   While the 51.7% versus 47.4% is pretty close jbog 08/17/18 12:43:05 PM
#220527   Mavyret’s US new-patient share=51.7%—the highest-ever weekly figure—in th DewDiligence 08/17/18 11:45:04 AM
#220526   This story broke one month ago—see #msg-142324338. DewDiligence 08/17/18 11:41:43 AM
#220525   FDA approves Opdivo monothearpy for third-line SCLC—the first DewDiligence 08/17/18 11:38:52 AM
#220524   EOLS—Apparently, Health Canada was more forgiving on CMC DewDiligence 08/17/18 11:32:07 AM
#220523   Good question. EPVantage omitted RT002 in their 2017 DewDiligence 08/17/18 11:30:25 AM
#220522   EOLS gets approval in Canada xavierprivas 08/17/18 08:42:09 AM
#220521   Louisiana seeking comments on 'Netflix' model for hepatitis jbog 08/16/18 10:39:11 PM
#220520   Yes, absolutely. Bickema 08/16/18 10:06:20 PM
#220519   Thanks! (eom) DewDiligence 08/16/18 04:50:07 PM
#220518   It's LenviMa ciotera 08/16/18 04:43:53 PM
#220517   MRK/Eisai—FDA approves Lenvina monothearpy in first-line HCC: DewDiligence 08/16/18 04:23:01 PM
#220516   Yes, absolutely. DewDiligence 08/16/18 03:56:47 PM
#220515   https://endpts.com/gilead-loses-key-patent-claims-for-sovaldi-in-china-opening-d caravon 08/16/18 03:48:50 PM
#220514   More news re TEVA: north40000 08/16/18 03:08:07 PM
#220513   Would you add RT002 to that list? Bickema 08/16/18 01:02:17 PM
#220512   TEVA+4%/REGN+2% on Fasinumab nominally-positive phase-3 data in OA: DewDiligence 08/16/18 11:53:59 AM
#220511   PTIE -50% on $11M direct offering https://twitter.com/mychartcoachcom/status/10 Titan V 08/16/18 10:54:35 AM
#220510   SBBP rescinds offering after 19% sell-off: DewDiligence 08/15/18 09:30:30 PM
#220509   Agreed! (eom) Titan V 08/15/18 03:25:53 PM
#220508   That list is based on a consensus of DewDiligence 08/15/18 02:20:17 PM
#220507   Most valuable unpartnered assets reveal a changing of Titan V 08/15/18 02:17:27 PM
#220506   Gilead loses key patent claims for Sovaldi in caravon 08/15/18 12:57:41 PM
#220505   Biotech Jim. Re the following in Whalatane 08/15/18 12:48:21 PM
#220504   EOLS makes CMO head of R&D—IOW, EOLS doesn’t DewDiligence 08/15/18 11:32:40 AM
#220503   Reuters on GSK/JNJ’s Cabotegravir/Edurant prospects: DewDiligence 08/15/18 11:27:10 AM
#220502   GILD – Chief Medical Officer, Andrew Cheng, MD, biotech_researcher 08/15/18 09:21:38 AM
#220501   Re: OMER biotech jim 08/15/18 08:56:11 AM
#220500   I think the biggest disruptive potential is with dewophile 08/15/18 08:34:17 AM
#220499   As to TA and chart action of OMER, biotech jim 08/15/18 08:12:37 AM
#220498   ATNM - News awaited traderin 08/15/18 05:46:57 AM
#220497   OMER down. BiotechJim What'd you expect from chart/data? Biowatch 08/14/18 09:18:11 PM
#220496   To an homologous regime. Here is other preclinical jondoeuk 08/14/18 02:10:19 PM
#220495   Gritstone—...This has been shown to induce greater numbers DewDiligence 08/14/18 01:34:02 PM
#220494   Gritstone will be using a heterologous prime-boost regime. jondoeuk 08/14/18 01:27:35 PM
#220493   BLUSF continuing to look very strong. May have ronpopeil 08/14/18 11:47:41 AM
#220492   RLM.L -50% on phase-2 failure: DewDiligence 08/14/18 10:51:25 AM
#220491   CCXI was downgraded by JPM: DewDiligence 08/14/18 10:43:36 AM
#220490   ARDS IPOs 2.30M* shares @$13.00—low-end of anticipated range: DewDiligence 08/14/18 10:41:20 AM
#220489   CCXI reports 2nd quarter results. Stock down 13% bladerunner1717 08/14/18 10:27:46 AM
#220488   ENTA’s current tax rate—excluding discrete items—is ~18%. DewDiligence 08/13/18 07:40:59 PM
#220487   Re: HCV in China Mayvret is not DewDiligence 08/13/18 11:08:59 AM
#220486   I was referring to clinical data analysis....sorry I n4807g 08/13/18 04:22:12 AM
#220485   Only 1 biotech company is debuting on the traderin 08/13/18 01:13:09 AM
#220484   Ok, Thanks. The article made it sound like DaveAu 08/12/18 10:01:07 PM
#220482   Guessing from the chart, it'll go down again Biowatch 08/12/18 09:07:27 PM
#220480   How much can companies charge now for whatever DewDiligence 08/12/18 08:59:33 PM
PostSubject